Tilray | TRLY - Pre Tax Profit

Stock Price
10.73
Daily Change
-0.20 -1.83%
Monthly
0.66%
Yearly
902.80%
Q1 Forecast
10.37

Tilray reported $-1.39B in Pre-Tax Profit for its fiscal quarter ending in March of 2025.





Pre Tax Profit Change Date
Acasti Pharma USD -938K 2.42M Sep/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Aurora Cannabis CAD 46.98M 66.36M Sep/2025
Avita Medical AUD -23.77M 12.2M Jun/2025
Canopy Growth CAD -1.42M 39.82M Sep/2025
Cronos Group USD 31.78M 70.78M Sep/2025
Dianthus Therapeutics USD -36.76M 5.13M Sep/2025
Divis Laboratories Ltd INR 8.54B 580M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
IQVIA Holdings USD 6.16B 5.84B Sep/2025
Knight Therapeutics CAD -1.92M 13.69M Sep/2025
Moderna USD -187M 631M Sep/2025
Organigram Holdings CAD -41.72M 25.52M Sep/2025
Organon & Co USD 243M 14M Sep/2025
Revvity USD 55.68M 115.97M Sep/2025
Tectonic Therapeutic USD -19.04M 25K Sep/2025
Tilray USD -1.39B 600.71M Mar/2025
Viatris USD -7.9M 209.2M Sep/2025
Xeris Pharmaceuticals USD 621K 2.55M Sep/2025